Subhallucinogenic Concentrations of Substituted Phenethylamines as a Novel Therapeutic Approach for Inflammatory and Neurological Disorders.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
13 Jul 2023
13 Jul 2023
Historique:
received:
20
05
2023
pmc-release:
13
07
2024
medline:
19
7
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
epublish
Résumé
This Patent Highlight presents a method to treat inflammatory or neurological disorders in subjects needing treatment. The method involves administering a therapeutically effective amount of a composition containing a subhallucinogenic concentration of substituted phenethylamine. The substituted phenethylamine may belong to the 2C-X family, including 2C-H, 2C-I, 2C-B, or 2C-E. The specific concentration depends on the chronic inflammation's severity, with 25 mg for mild, 50 mg for moderate, and 100 mg for severe cases.
Identifiants
pubmed: 37465310
doi: 10.1021/acsmedchemlett.3c00220
pmc: PMC10350937
doi:
Types de publication
Editorial
Langues
eng
Pagination
884-885Informations de copyright
Published 2023 by American Chemical Society.
Déclaration de conflit d'intérêts
The author declares no competing financial interest.
Références
J Med Chem. 2023 Apr 13;66(7):4417-4433
pubmed: 36971365
Neuropharmacology. 2023 Feb 1;223:109257
pubmed: 36179919
Neuropharmacology. 2023 Mar 1;225:109375
pubmed: 36529260
J Transl Med. 2023 Feb 25;21(1):149
pubmed: 36829232
Biol Psychiatry. 2023 Jun 15;93(12):1061-1070
pubmed: 36715317
Drug Discov Today. 2023 Apr;28(4):103518
pubmed: 36758932